We are committed to providing personalised, evidence-based cancer care with compassion and excellence. Every patient's journey is unique, and we are here to support you at every step — from diagnosis to recovery and beyond.
Read more about us →
Selected case studies from our oncology and regenerative medicine programs.
A total of 468 patients were studied under controlled trial, all suffering from breast cancer. Organ specific killer stem cells were used. Patients with non-metastatic disease received 60 million cells; metastatic cases received 80 million.
Read more →In a randomized controlled study 300 patients suffering from hepatocellular carcinoma with raised alpha-feto protein levels were transfused with organ-specific killer stem cells alongside sorafenib and post-stem-cell boosters.
Read more →Patients suffering from squamous cell carcinoma of the mouth were treated using organ-specific killer stem cells modified from umbilical cord stem cells with strong post-treatment regression observed.
Read more →A controlled trial in chronic liver cirrhosis patients used hepatic regenerative stem cells derived from umbilical cord, with marked improvement in liver function tests and reduction of ascites within weeks.
Read more →In a randomized controlled study 300 patients suffering from chronic kidney failure on regular dialysis received 40 million kidney-specific stem cells. Creatinine dropped progressively and most patients halted dialysis dependency.
Read more →Patients suffering from osteosarcoma were treated using organ-specific killer stem cells combined with kinase inhibitors as post-stem-cell boosters, achieving substantial tumour regression.
Read more →Patients suffering from colon cancer were transfused with intestine-specific killer stem cells. With sorafenib and pazopanib boosters, complete tumour regression was achieved over 4–6 months of therapy.
Read more →A controlled trial of ovarian cancer patients used ovary-specific killer stem cells modified from pluripotent umbilical-cord cells, with PET-confirmed cancer-free outcomes after the full booster regimen.
Read more →Stomach cancer patients were treated with stomach-specific killer stem cells along with kinase inhibitor boosters, with marked regression on imaging within weeks and full clearance on PET at 6–7 months.
Read more →A total of 340 patients with dementia received 30 million neural stem cells modified from umbilical cord. Memory and orientation improved within the first week, with full recovery in 60–90 days.
Read more →Cerebral palsy patients were treated with umbilical-cord-derived neural stem cells. Motor coordination, speech and cognitive milestones improved progressively across the follow-up period.
Read more →Patients with autism and ADHD were treated with umbilical-cord-derived neural stem cells, with measurable improvement in attention, social engagement and behavioural metrics.
Read more →Down's syndrome patients received neural stem cells from umbilical cord origin, with developmental, cognitive and motor improvements documented over the treatment course.
Read more →Lymphoma patients received lymphocyte-specific killer stem cells from umbilical cord with kinase inhibitor boosters; full haematological recovery and PET-negative results were achieved.
Read more →A total of 140 leukemia patients (CLL and CML) were transfused with lymphocyte-specific killer stem cells. Blood counts normalized within 2 months and patients were declared cancer-free.
Read more →Multiple myeloma patients received plasma-cell-targeted killer stem cells with boosters; bone marrow studies and imaging confirmed remission within the follow-up window.
Read more →Patients with leiomyosarcoma received organ-specific killer stem cells with kinase inhibitor boosters, resulting in measurable tumour shrinkage and eventual PET-negative status.
Read more →Prostate cancer patients received prostate-specific killer stem cells along with boosters; PSA levels normalized and PET imaging confirmed clearance after 6 months of therapy.
Read more →Cholangiocarcinoma patients were treated with bile-duct-specific killer stem cells and kinase inhibitors. Bilirubin normalized, jaundice resolved, and tumour mass cleared on follow-up imaging.
Read more →A total of 386 patients with colon adenocarcinoma — including those with liver and kidney mets — were transfused with organ-specific killer stem cells. PET scans at 6 months were negative for cancer.
Read more →